外用7.5%氨苯砜凝胶治疗寻常性躯干痤疮
Management of Truncal Acne Vulgaris with Topical Dapsone 7.5% Gel.
作者信息
Del Rosso James Q, Kircik Leon, Tanghetti Emil
机构信息
Dr. Del Rosso is with JDR Dermatology Research and Thomas Dermatology in Las Vegas, Nevada, and is also Adjunct Clinical Professor at Touro University Nevada in Henderson, Nevada.
Dr. Kircik is Clinical Associate Professor of Dermatology at Icahn School of Medicine at Mount Sinai in New York, New York, and is Medical Director at Indiana University Medical Center in Indianapolis, Indiana.
出版信息
J Clin Aesthet Dermatol. 2018 Aug;11(8):45-50. Epub 2018 Aug 1.
The majority of available data on the prevalence, grading, and management of acne vulgaris (AV) are based on studies that evaluate facial AV. Data are limited in all of these areas with truncal AV. This study evaluates the efficacy and safety of topical management of truncal AV involving the chest and back in a three-center, open-label, 16-week study. Enrolled subjects (N=20), 12 years of age or older, applied dapsone 7.5% gel once daily as monotherapy. The primary endpoint of the study was the percent of subjects who achieved a two-grade improvement and a rating of clear or almost clear based on the Investigator Global Assessment scale. Secondary endpoints included percent reductions of inflammatory, non-inflammatory (comedonal), and total lesions at Week 16 compared to baseline. Tolerability and safety were assessed over the duration of the study.
大多数关于寻常痤疮（AV）的患病率、分级和治疗的数据都基于评估面部AV的研究。在所有这些方面，躯干AV的数据都很有限。本研究在一项三中心、开放标签、为期16周的研究中，评估了涉及胸部和背部的躯干AV局部治疗的有效性和安全性。入选的受试者（N = 20）年龄在12岁及以上，每天一次使用7.5%氨苯砜凝胶作为单一疗法。该研究的主要终点是根据研究者整体评估量表达到两级改善且评级为清除或几乎清除的受试者百分比。次要终点包括与基线相比，在第16周时炎症性、非炎症性（粉刺性）和总皮损的减少百分比。在研究期间评估耐受性和安全性。
Zotero 插件